Elsevier

Bone

Volume 52, Issue 1, January 2013, Pages 56-62
Bone

Original Full Length Article
High serum total homocysteine levels accelerate hip bone loss in healthy premenopausal women and men

https://doi.org/10.1016/j.bone.2012.09.022Get rights and content

Abstract

Introduction

Despite extensive evidence demonstrating the direct, detrimental role of homocysteine on bone metabolism, the effects of serum total homocysteine (tHcy) on bone loss are still equivocal. In the present study, we performed a longitudinal study on healthy participants of various ages of both sexes in order to investigate the association between serum tHcy concentrations and annualized changes in bone mineral density (BMD).

Methods

A total of 460 Koreans  30 years of age received comprehensive, routine health examinations for an average period of 3 years. The BMD at proximal femur sites was measured with dual-energy X-ray absorptiometry using the same equipment at baseline and follow-up.

Results

After adjusting for potential confounders, the rates of bone loss at the proximal femur sites were significantly accelerated in a dose–response fashion across increasing tHcy concentrations in premenopausal women and men, but not in postmenopausal women. Consistently, compared with subjects in the lowest tHcy quartile, premenopausal women in the third and/or highest tHcy quartile and men in the highest tHcy quartile showed significantly higher rates of bone loss at all proximal femur sites (p = 0.015–0.048) and at the total femur and femur neck (p = 0.008–0.013), respectively. In contrast, there were no differences in terms of bone loss among the tHcy quartiles for postmenopausal women.

Conclusion

These data provide the first clinical evidence that increased tHcy levels could be an independent risk factor for the future deterioration of bone mass in premenopausal women and men.

Highlights

► Serum tHcy level was significantly higher in men than women, and, among women, in postmenopausal women than premenopausal women. ► Higher serum tHcy concentrations were independently associated with accelerated hip bone loss in premenopausal women and men. ► In contrast, there was no relationship between serum tHcy levels and hip bone loss in postmenopausal women. ► First clinical evidence demonstrating that the detrimental effects of tHcy on bone loss are predominant in relatively younger subjects.

Introduction

Many lines of evidence now indicate that elevation of homocysteine and its disulfide derivatives (tHcy) has direct detrimental effects on bone metabolism. Homocysteine may interfere with bone collagen cross-links, thereby increasing bone fragility [1]. In a murine experimental model, rats with elevated tHcy demonstrated severe trabecular bone loss, altered microarchitectural parameters, and decreased mechanical strength in the femoral neck [2]. In addition, our in vitro studies have reported that homocysteine induces apoptosis in bone marrow stromal cells via the reactive oxygen species (ROS)-mediated mitochondrial pathway and NF-kappa B activation [3], whereas it promotes bone resorption by stimulating p38 mitogen-activated protein kinase (MAPK) activity and the generation of intracellular ROS in osteoclasts [4]. The first clinically relevant evidence of these in vitro and animal findings was observed in patients with homocystinuria due to cystathionine beta-synthase deficiency, an inborn error of metabolism that is characterized by very high plasma concentrations of tHcy and, among several clinical manifestations, premature osteoporosis and fractures [5].

Based on these findings, numerous epidemiological studies have been performed to assess the role of serum tHcy as a risk factor for osteoporosis-related phenotypes. All prospective trials that enrolled > 1000 patients found a significant positive relationship between tHcy and osteoporotic fractures [6], [7], [8], [9]. In contrast, studies on the association between tHcy and bone mineral density (BMD) have yielded inconsistent results [10]. However, because almost all of these studies were cross-sectional in design [11], [12], the role of tHcy in bone mass could not be appropriately investigated. Furthermore, the only two studies of longitudinal bone loss that have been previously reported were based on data from elderly patients > 75 years of age on average and had contradictory findings [13], [14]. Thus, the effects of tHcy on bone density are still equivocal.

It is well known that the biologic differences between men and women, as well as menopause status, are important factors that influence bone metabolism, implying that the effects of various risk factors on bone health could be different depending on the sex and menopause status of the individual patient. Actually, several epidemiological studies have reported different relationships of serum tHcy levels with osteoporosis-related phenotypes in men and women [7], [9], [12]. In the present study, we performed a longitudinal study on healthy pre- and postmenopausal women and men in order to investigate the association between serum tHcy concentrations and annualized changes in BMD.

Section snippets

Study participants

This was a 3-year longitudinal health promotion center-based study. The study population consisted of subjects  30 years of age who had undergone comprehensive routine health examinations at the Asan Medical Center (AMC, Seoul, Republic of Korea) in 2007 and had returned for follow-up examinations in 2010; BMD and serum tHcy concentrations were measured during these examinations. The examinations consisted of extensive screening tests for the early detection of malignancy, diabetes, osteoporosis,

Results

The baseline characteristics of the 460 study subjects are shown in Table 1. The mean ages of the pre- and postmenopausal women and men were 45.6 ± 3.5 years (range: 30–54 years), 55.6 ± 6.2 years (range: 44–80 years), and 55.0 ± 8.4 years (range: 35–80 years), respectively. BMI and the percentage of current smokers and drinkers were significantly higher in men than in women, whereas the percentage of subjects who consumed dairy products was higher in women than in men. Women demonstrated significantly

Discussion

In this longitudinal study of 460 healthy Koreans, we found that the rates of bone loss over 3 years at multiple proximal femur sites significantly accelerated in a dose–response manner as the tHcy concentration increased, even after adjusting for potential confounding factors in premenopausal women and men. These data provide the first clinical evidence that increased tHcy levels could be an independent risk factor for future deterioration of bone mass in premenopausal women and men.

Although

Acknowledgments

This study was supported by grants from the Korea Health Technology R&D Project and the National Project for Personalized Genomic Medicine, Ministry of Health & Welfare, Republic of Korea (project nos. A110536 and A111218-GM03, respectively).

References (28)

  • S.H. Mudd et al.

    The natural history of homocystinuria due to cystathionine beta-synthase deficiency

    Am J Hum Genet

    (1985)
  • J.B. van Meurs et al.

    Homocysteine levels and the risk of osteoporotic fracture

    N Engl J Med

    (2004)
  • R.R. McLean et al.

    Homocysteine as a predictive factor for hip fracture in older persons

    N Engl J Med

    (2004)
  • C.G. Gjesdal et al.

    Plasma homocysteine, folate, and vitamin B 12 and the risk of hip fracture: the Hordaland Homocysteine Study

    J Bone Miner Res

    (2007)
  • Cited by (13)

    • Moderate hyperhomocysteinemia induced by short-term dietary methionine overload alters bone microarchitecture and collagen features during growth

      2017, Life Sciences
      Citation Excerpt :

      In this regard, homocysteine has been identified as a potential risk factor for osteoporosis and bone fragility [12,14]. Epidemiological studies investigated the relationship between homocysteine levels and bone mineral density (BMD) – a surrogate marker of bone strength, showing a decreased BMD [15] and subsequently an increased fracture risk in the patients with hyperhomocysteinemia [16]. Moreover, negative effects of hyperhomocysteinemia on bone were found to be partly independent of the decrease in BMD [14].

    • One carbon metabolism and bone homeostasis and remodeling: A review of experimental research and population studies

      2016, Biochimie
      Citation Excerpt :

      Similarly, current data in human population have brought indecisive results. Several longitudinal studies suggested a correlation between HCY, vitamin B status and fracture risk [20,21] or bone loss [22,23]. However, studies investigating the impact of B vitamin supplementation have brought inconsistent effects on fracture prevention [24–27] and no effect on BMD [25,28,29].

    • Association between premature ovarian failure, polymorphisms in MTHFR and MTRR genes and serum homocysteine concentration

      2016, Reproductive BioMedicine Online
      Citation Excerpt :

      POF patients who had heterozygous and/or mutant-type genotypes of MTHFR C667T/A1289C and MTRR A66G displayed increased serum Hcy concentrations and may be more susceptible to cardiovascular disease and/or osteoporosis and need more attention and protection. Hcy is likely to be a potential connection between POF and divergent long-term effects such as cardiovascular disease and bone loss (Kim et al., 2013; Veeranna et al., 2011). Dynamic monitoring of serum Hcy concentrations in POF patients could be helpful in the selection of treatment options and the evaluation of clinical outcomes.

    • B-vitamins and bone in health and disease: The current evidence

      2014, Proceedings of the Nutrition Society
    • B-vitamins and bone in health and disease: The current evidence

      2014, Proceedings of the Nutrition Society
    View all citing articles on Scopus
    View full text